title: Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.
abstract: Previous studies have found a strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome in Asian areas including Taiwan, Hongkong and Thailand. This study explores the association between HLA-B*1502 allele and carbamazepine-induced cutaneous adverse reactions in Han Chinese of southern China mainland, and find the genetic marker that can predict carbamazepine-induced cutaneous adverse reactions. HLA-B*1502 allele genotyping was performed by a polymerase chain reaction-sequence specific primers (PCR-SSP) method in 48 Han Chinese subjects who had carbamazepine-induced cutaneous adverse reactions, including 9 severe cutaneous adverse reaction patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and 39 cutaneous adverse reaction patients with maculopapular eruption (MPE). Meanwhile 80 carbamazepine-tolerant controls and 62 healthy individuals were also tested. The frequency of HLA-B*1502 allele among SJS/TEN patients (100%) is significantly higher than carbamazepine-tolerant controls (13.75%, P<0.001) and healthy individuals (17.74%, P<0.001). But the frequency between MPE patients and carbamazepine-tolerant controls (25.64% vs.13.75%, P=0.110) did not have any significant difference. The data showed that HLA-B*1502 allele is strongly associated with carbamazepine-induced SJS/TEN but not MPE in Han Chinese of southern China mainland.
authors.affiliation: Department of Neurology, The First Affiliated Hospital of Sun Yet-sen University, Guangzhou, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Jue-qian
authors.initials: JQ
authors.lastname: Zhou
authors.forename: Lie-min
authors.initials: LM
authors.lastname: Zhou
authors.forename: Zi-yi
authors.initials: ZY
authors.lastname: Chen
authors.forename: Zi-yan
authors.initials: ZY
authors.lastname: Fang
authors.forename: Shu-da
authors.initials: SD
authors.lastname: Chen
authors.forename: Li-bai
authors.initials: LB
authors.lastname: Yang
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Cai
authors.forename: Qi-lin
authors.initials: QL
authors.lastname: Dai
authors.forename: Hua
authors.initials: H
authors.lastname: Hong
authors.forename: Hong-xuan
authors.initials: HX
authors.lastname: Wang
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D002681:China / Q000453:epidemiology; D004247:DNA / Q000235:genetics; D003875:Drug Eruptions / Q000208:ethnology / Q000235:genetics* / Q000473:pathology; D005260:Female; D005838:Genotype; D015235:HLA-B Antigens / Q000235:genetics*; D059910:HLA-B15 Antigen; D006801:Humans; D008297:Male; D008875:Middle Aged; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012867:Skin / Q000473:pathology; D013262:Stevens-Johnson Syndrome / Q000150:complications / Q000208:ethnology / Q000235:genetics
chemical_list: D000927:Anticonvulsants; D015235:HLA-B Antigens; C483536:HLA-B*15:02 antigen; D059910:HLA-B15 Antigen; D002220:Carbamazepine; D004247:DNA